In melanoma, most anti-cancer therapy and treatment approaches commonly targeted serine/threonine protein kinase inhibitors, particularly those involved in the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways [11]. This evidence concerns the gene AKT1 and melanoma.